Comparative Pharmacology
Head-to-head clinical analysis: KAITLIB FE versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAITLIB FE versus PHILITH.
KAITLIB FE vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KAITLIB FE (levonorgestrel/ethinyl estradiol/ferrous fumarate) is a combined hormonal contraceptive. Levonorgestrel is a progestogen that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that stabilizes the endometrium and provides cycle control. The added ferrous fumarate is an iron supplement to treat iron deficiency anemia.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
One tablet (norethindrone 1 mg and ethinyl estradiol 0.02 mg, with ferrous fumarate 35 mg) orally once daily for 28 days (21 active pills, 7 placebo/iron pills).
1 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinically significant for once-daily dosing
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Renal: 40-60% as unchanged drug; biliary: 20-30% as metabolites; fecal: 10-20%
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive